Education
About Us
Working with TipRanks
Follow Us
Amgen Inc (GB:0R0T)
:0R0T
0R0T Stock Chart & Stats
Day’s Range― - ―
52-Week Range$253.20 - $346.67
Previous CloseN/A
Volume4.58K
Average Volume (3M)N/A
Market Cap
$171.31B
Enterprise Value$190.17B
Total Cash (Recent Filing)$11.97B
Total Debt (Recent Filing)$60.10B
Price to Earnings (P/E)43.9
Beta0.42
Next Earnings
Apr 23, 2025EPS Estimate
4.29Next Dividend Ex-Date
May 16, 2025Dividend Yield2.79%
Share Statistics
EPS (TTM)7.55
Shares Outstanding537,204,960
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.11
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit9.25
Enterprise Value/Ebitda14.24
Forecast
1Y Price Target
$329.92Price Target Upside3.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceNon-GAAP EPS of $5.31 exceeded expectations, indicating strong financial performance.
Product GrowthRepatha and Tezspire have been experiencing significant growth, with Repatha growing 35% year-over-year on volume and Tezspire growing 70% year-over-year.
Bears Say
Regulatory ChallengesThe Phase 1 study of AMG 513 for obesity has been placed on clinical hold by the FDA.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.18% Insiders
21.42% Mutual Funds
18.60% Other Institutional Investors
32.51% Public Companies and Individual Investors
0R0T FAQ
What was Amgen Inc’s price range in the past 12 months?
Amgen Inc lowest share price was $253.20 and its highest was $346.67 in the past 12 months.
What is Amgen Inc’s market cap?
Amgen Inc’s market cap is $171.31B.
When is Amgen Inc’s upcoming earnings report date?
Amgen Inc’s upcoming earnings report date is Apr 23, 2025 which is in 42 days.
How were Amgen Inc’s earnings last quarter?
Amgen Inc released its earnings results on Feb 04, 2025. The company reported $5.31 earnings per share for the quarter, beating the consensus estimate of $5.091 by $0.219.
Is Amgen Inc overvalued?
According to Wall Street analysts Amgen Inc’s price is currently Undervalued.
Does Amgen Inc pay dividends?
Amgen Inc pays a Quarterly dividend of $9.13 which represents an annual dividend yield of 2.79%. See more information on Amgen Inc dividends here
What is Amgen Inc’s EPS estimate?
Amgen Inc’s EPS estimate is 4.29.
How many shares outstanding does Amgen Inc have?
Amgen Inc has 537,204,960 shares outstanding.
What happened to Amgen Inc’s price movement after its last earnings report?
Amgen Inc reported an EPS of $5.31 in its last earnings report, beating expectations of $5.091. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Amgen Inc?
Currently, no hedge funds are holding shares in GB:0R0T
---
Amgen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$329.92 (3.02% Upside)
$329.92 (3.02% Upside)
Blogger Sentiment
Bullish
GB:0R0T Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $20.7M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
19.33%
12-Months-Change
Fundamentals
Return on Equity
67.55%
Trailing 12-Months
Asset Growth
-5.47%
Trailing 12-Months
Company Description
Amgen Inc
Founded in 1980, California-based Amgen, Inc. is one of the world's leading biotechnology companies, which is engaged in the discovery, development, manufacture and marketing of human therapeutics. It primarily focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas.
---
0R0T Company Deck
---
0R0T Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong performance in 2024 with significant growth in product sales, particularly in oncology and biosimilars. The successful integration of Horizon and robust financial results further reinforce Amgen's position for continued growth. However, challenges such as the upcoming patent expiration for denosumab and expected price declines pose potential risks.Read More>---
0R0T Revenue Breakdown
13.09% Prolia
9.92% Enbrel
6.66% XGEVA
6.65% Repatha
63.69% Other
---
0R0T Stock 12 Month Forecast
Average Price Target
$329.92
▲(3.02% Upside)
Technical Analysis
Best Analysts Covering 0R0T
1 Year
1 Year Success Rate
31/36 ratings generated profit
1 Year Average Return
+15.11%
reiterated a buy rating 3 days ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 77.14% of your transactions generating a profit, with an average return of +15.11% per trade.
---